{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T16:58:58Z","timestamp":1772816338086,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1016\/j.schres.2010.02.1066","type":"journal-article","created":{"date-parts":[[2010,3,27]],"date-time":"2010-03-27T08:22:54Z","timestamp":1269678174000},"page":"153-159","source":"Crossref","is-referenced-by-count":9,"title":["Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities"],"prefix":"10.1016","volume":"119","author":[{"given":"Leslie","family":"Citrome","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ari","family":"Jaffe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jerome","family":"Levine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.schres.2010.02.1066_bib1","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1742-1241.2008.01900.x","article-title":"Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic","volume":"63","author":"Citrome","year":"2009","journal-title":"Int. J. Clin. Pract."},{"issue":"8","key":"10.1016\/j.schres.2010.02.1066_bib2","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/j.1742-1241.2009.02142.x","article-title":"Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic","volume":"63","author":"Citrome","year":"2009","journal-title":"Int. J. Clin. Pract."},{"issue":"2","key":"10.1016\/j.schres.2010.02.1066_bib3","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1742-1241.2009.02240.x","article-title":"Paliperidone palmitate\u2014review of the efficacy, safety, and cost of a new second-generation depot antipsychotic medication","volume":"64","author":"Citrome","year":"2010","journal-title":"Int. J. Clin. Pract."},{"issue":"3","key":"10.1016\/j.schres.2010.02.1066_bib4","first-page":"321","article-title":"Utilization of depot neuroleptic medication in psychiatric inpatients","volume":"32","author":"Citrome","year":"1996","journal-title":"Psychopharmacol. Bull."},{"issue":"4","key":"10.1016\/j.schres.2010.02.1066_bib5","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1023\/A:1022130130855","article-title":"Utilization of valproate: extent of inpatient use in the New York State Office of Mental Health","volume":"69","author":"Citrome","year":"1998","journal-title":"Psychiatr. Q."},{"issue":"5","key":"10.1016\/j.schres.2010.02.1066_bib6","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1176\/appi.ps.51.5.634","article-title":"Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998","volume":"51","author":"Citrome","year":"2000","journal-title":"Psychiatr. Serv."},{"issue":"10","key":"10.1016\/j.schres.2010.02.1066_bib7","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1176\/appi.ps.53.10.1212","article-title":"Use of mood stabilizers among patients with schizophrenia, 1994\u20132001","volume":"53","author":"Citrome","year":"2002","journal-title":"Psychiatr. Serv."},{"issue":"9","key":"10.1016\/j.schres.2010.02.1066_bib8","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1176\/appi.ps.55.9.1006","article-title":"Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients","volume":"55","author":"Citrome","year":"2004","journal-title":"Psychiatr. Serv."},{"issue":"4","key":"10.1016\/j.schres.2010.02.1066_bib9","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/01.jcp.0000169623.30196.b9","article-title":"Dosing of second-generation antipsychotic medication in a state hospital system","volume":"25","author":"Citrome","year":"2005","journal-title":"J. Clin. Psychopharmacol."},{"issue":"12","key":"10.1016\/j.schres.2010.02.1066_bib10","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.4088\/JCP.v66n1203","article-title":"Dosing of quetiapine in schizophrenia: how clinical practice differs from registration studies","volume":"66","author":"Citrome","year":"2005","journal-title":"J. Clin. Psychiatry"},{"issue":"8","key":"10.1016\/j.schres.2010.02.1066_bib11","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1176\/ps.2006.57.8.1132","article-title":"Incidence, prevalence, and surveillance for diabetes in New York State psychiatric hospitals, 1997\u20132004","volume":"57","author":"Citrome","year":"2006","journal-title":"Psychiatr. Serv."},{"issue":"1","key":"10.1016\/j.schres.2010.02.1066_bib12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1176\/ps.2007.58.1.11","article-title":"Datapoints: the ups and downs of dosing second-generation antipsychotics","volume":"58","author":"Citrome","year":"2007","journal-title":"Psychiatr. Serv."},{"issue":"7","key":"10.1016\/j.schres.2010.02.1066_bib13","doi-asserted-by":"crossref","first-page":"975","DOI":"10.4088\/JCP.08m04531","article-title":"How dosing of ziprasidone in a state hospital system differs from product labeling","volume":"70","author":"Citrome","year":"2009","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2010.02.1066_bib14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1176\/ps.2010.61.1.9","article-title":"Datapoints: depot antipsychotic use in New York State hospitals, 1994 to 2009","volume":"61","author":"Citrome","year":"2010","journal-title":"Psychiatr. Serv."},{"issue":"12","key":"10.1016\/j.schres.2010.02.1066_bib15","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1345\/aph.1E085","article-title":"Long-acting injectable risperidone","volume":"38","author":"Ehret","year":"2004","journal-title":"Ann. Pharmacother."},{"issue":"2","key":"10.1016\/j.schres.2010.02.1066_bib16","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2165\/00023210-200418020-00005","article-title":"Long-acting risperidone: a review of its use in schizophrenia","volume":"18","author":"Harrison","year":"2004","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.schres.2010.02.1066_bib17","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/pds.783","article-title":"Antipsychotic medication coprescribing in a large state hospital system","volume":"12","author":"Jaffe","year":"2003","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"Suppl 17","key":"10.1016\/j.schres.2010.02.1066_bib18","first-page":"3","article-title":"Efficacy and effectiveness of first- and second-generation antipsychotics in schizophrenia","volume":"64","author":"Jaffe","year":"2003","journal-title":"J. Clin. Psychiatry"},{"issue":"7","key":"10.1016\/j.schres.2010.02.1066_bib19","doi-asserted-by":"crossref","first-page":"585","DOI":"10.4088\/JCP.v63n0708","article-title":"A naturalistic study of risperidone treatment outcome using prognosis-adjusted discharge rates in New York State inpatients","volume":"63","author":"Javitt","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2010.02.1066_bib20","unstructured":"Johnson and Johnson, 2009. FDA Approves Invega Sustenna for the Acute and Maintenance Treatment of Schizophrenia. Press release, 31 July 2009. Available at: http:\/\/www.jnj.com\/connect\/news\/all\/20090731_153000. Accessed 2 September 2009."},{"key":"10.1016\/j.schres.2010.02.1066_bib21","series-title":"Mental Health United States 2002","first-page":"199","article-title":"Antipsychotic Medication Utilization in a State Mental Hospital System, 1994\u20132000, Chap. 15","author":"Levine","year":"2004"},{"issue":"2","key":"10.1016\/j.schres.2010.02.1066_bib22","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1017\/S0033291700030907","article-title":"The role of depot neuroleptics in the treatment of schizophrenic patients","volume":"9","author":"Levine","year":"1979","journal-title":"Psychol. Med."},{"issue":"4","key":"10.1016\/j.schres.2010.02.1066_bib23","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s11126-009-9111-9","article-title":"Duration of pharmacotherapy with long-acting injectable risperidone in the treatment of schizophrenia","volume":"80","author":"Mohamed","year":"2009","journal-title":"Psychiatr. Q."},{"issue":"1","key":"10.1016\/j.schres.2010.02.1066_bib24","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1600-0447.2006.00980.x","article-title":"Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care","volume":"116","author":"Niaz","year":"2007","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2010.02.1066_bib25","unstructured":"Otsuka Pharmaceutical Development & Commercialization, Inc., 2008. Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients with Schizophrenia (ASPIRE). Registry entry, 7 Aug 2008. Available at: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00731549. Accessed 31 Oct 2008."},{"issue":"3","key":"10.1016\/j.schres.2010.02.1066_bib26","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1185\/03007990903488670","article-title":"Treatment retention with risperidone long-acting injection: 24-month results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR) in six countries","volume":"26","author":"Peuskens","year":"2010","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.schres.2010.02.1066_bib27","article-title":"Risperidone long-acting injection: factors associated with changes in bed stay and hospitalisation in a 3-year naturalistic follow-up","author":"Taylor","year":"2009","journal-title":"J. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.schres.2010.02.1066_bib28","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1017\/S1461145705006309","article-title":"Prospective 6-month follow-up of patients prescribed risperidone long-acting injection: factors predicting favourable outcome","volume":"9","author":"Taylor","year":"2006","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.schres.2010.02.1066_bib29","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1600-0447.2009.01352.x","article-title":"Risperidone long-acting injection: a 6-year mirror-image study of healthcare resource use","volume":"120","author":"Taylor","year":"2009","journal-title":"Acta Psychiatr. Scand."},{"issue":"2","key":"10.1016\/j.schres.2010.02.1066_bib30","doi-asserted-by":"crossref","first-page":"196","DOI":"10.4088\/JCP.08m04427","article-title":"Risperidone long-acting injection: a prospective 3-year analysis of its use in clinical practice","volume":"70","author":"Taylor","year":"2009","journal-title":"J. Clin. Psychiatry"},{"issue":"10","key":"10.1016\/j.schres.2010.02.1066_bib31","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1176\/ps.46.10.1049","article-title":"Postdischarge medication compliance of inpatients converted from an oral to a depot neuroleptic regimen","volume":"46","author":"Weiden","year":"1995","journal-title":"Psychiatr. Serv."},{"issue":"1","key":"10.1016\/j.schres.2010.02.1066_bib32","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1600-0447.2006.00766.x","article-title":"Health resource utilization associated with switching to risperidone long-acting injection","volume":"114","author":"Young","year":"2006","journal-title":"Acta Psychiatr. Scand."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996410011618?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996410011618?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,27]],"date-time":"2019-05-27T18:00:53Z","timestamp":1558980053000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996410011618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":32,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S0920996410011618"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2010.02.1066","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}